Trials / Withdrawn
WithdrawnNCT04555603
Axitinib Therapy Management Study
Retrospective Analysis of Axitinib Treatment Optimization and Management of Selected Immune Related Adverse Events of Checkpoints Inhibitors
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of the study is to describe axitinib therapy management through use of the data to be generated by ConcertAI
Detailed description
not mandatory
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inlyta | axitinib |
| DRUG | Bavencio | avelumab |
| DRUG | Keytruda | Pembrolizumab |
Timeline
- Start date
- 2020-09-15
- Primary completion
- 2021-02-22
- Completion
- 2021-02-22
- First posted
- 2020-09-18
- Last updated
- 2023-11-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04555603. Inclusion in this directory is not an endorsement.